FDA’s Quality Management Maturity Program – Why should CDMOs adhere to the new CDER’s Rating System

As a Contract Development and Manufacturing Organization (CDMO), our primary goal is to produce high-quality pharmaceuticals that meet the needs of clients and ensure the safety and well-being of the final consumers – patients. To achieve this, it is essential to have an in-depth understanding of the FDA’s Quality Management Maturity (QMM) program. The objective of this webinar is to explore the QMM program and its benefits, including the rating system currently being developed by the FDA’s Center for Drug Evaluation and Research (CDER) to incentivize drug manufacturers to achieve QMM. We will also explore the possible challenges that CDMOs will face in achieving high scores and the steps to overcome these challenges, to ensure they deliver high-quality products.